글로벌 In Vivo 계약 연구 기관(CRO) 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

계약 연구 기관(CRO) 서비스를 통해 스폰서/제조업체는 생산 능력과 자체 프로세스 개선에만 전념할 수 있습니다. 게다가 약물 발견에서 시판 후 감시에 이르기까지 다양한 서비스를 통해 중소 규모 생명공학 및 제약 기업이 핵심 전문 분야를 넘어선다고 생각하는 것을 아웃소싱하기가 더 쉬워졌습니다.

Data Bridge Market Research는 2021년에 39억 4천만 달러였던 생체내 계약 연구 기관(CRO) 시장이 2029년까지 74억 6천만 달러로 급증할 것으로 분석했으며, 예측 기간 동안 8.30%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

In-vivo 계약 연구 기관은 생체 내에서 생물약학 연구를 수행하는 계약 연구 기관(CRO)입니다(IV-CRO). In-vivo CRO는 생물학이 인기 면에서 소분자 약물을 앞지르면서 더욱 널리 퍼지고 있습니다. CRO는 mAb 개발에서 경쟁이 치열하기 때문에 바이오시밀러 개발에 더 집중하고 있습니다. 파이프라인의 초점은 기존 mAb에서 벗어나 이중 특이성 또는 바이오시밀러로 이동하고 있습니다. 활성 제약 성분의 임상 규모 제조에 대한 수요가 증가함에 따라 통합 계약 연구, 개발 및 제조 기관(CDMO)은 모든 분야에서 매출 발자국을 늘리고 있습니다.

보고 범위 및 시장 세분화

In Vivo Contract Research Organization (CRO) Market Dynamics

Drivers

• Increase the number of research and development (R&D) activities

Many molecules are about to expire due to a patent cliff, which is projected to fuel the biosimilar business. As a result, the number of research and development (R&D) efforts done by enterprises to commercialize the generic molecule is projected to rise. The need for cro service providers will be fueled by the race to launch the molecule on a reasonable timetable and budget.

• Preclinical studies

Tier 1 pharma and biotechnology businesses most frequently outsource toxicology and pharmacokinetic investigations in preclinical studies. The time and cost effectiveness given by the providers of such services have been highlighted as the main motivations for outsourcing activities. These activities are likely to increase throughout the projection period as pharmaceutical companies increase their attention and R&D budget allocation for the creation of new products.

• Rise in number of therapies

 The number of late-stage pipeline therapies increased by 19 percent to 849 (2018) from 711 (2017), owing to the increasing number of precision therapies in the oncology pipeline and the large number of pipeline medications. The use of oncology-based in-vivo cro aids in the development of new treatments for cancer prevention, analysis, and treatment, which is expected to drive the global market forward.

Opportunities

An increase in the geriatric population has also supported the expansion of the oncology-based in vivo contract research organization (CRO) market. Due to the increasing number of specific therapies in the oncology pipeline and the presence of a large number of pipeline drugs, as well as the use of oncology-based in-vivo cro to aid in the development of novel therapies for the diagnosis, prevention, and treatment of patients, the number of late-stage pipeline therapies increased from 711 in 2017 to 849 in 2018, a 19% increase, which is expected to further boost market growth.

Restraints/Challenges

However, some constraints affecting the in vivo contract research organization (CRO) market revenue growth include pharmaceutical companies' shifting preference for outsourcing clinical and preclinical trials in order to focus on their core business, high clinical trial costs, and CRO quality issues. Furthermore, other issues, such as the availability of suitable animals for certain testing, are hampering the in vivo contract research organization (CRO) market revenue growth.

This in vivo contract research organization (CRO) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the In vivo CRO market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on In Vivo Contract Research Organization (CRO) Market

While planning, developing, and caring for others and their families during COVID-19, health professionals are nervous, overworked, and financially insecure. We must help them accomplish their duties, stay safe, and stay alive. Future research should look on health professionals' worries and coping methods during pandemics. The market suffered a setback as a result of the introduction of tight lockdown measures and travel restrictions during COVID-19. However, this pandemic has brought to light an even larger need for a paradigm shift in cancer research.

Global In Vivo Contract Research Organization (CRO) Market Scope

The in vivo contract research organization (CRO) market is segmented on the basis of product, applications and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product type

•  Rodent Based
•  Non Rodent Based

Applications 

• Autoimmune
•  Pain Management
•  Oncology
•  CNS Conditions
•  Diabetes
•  Obesity
•  Others

In Vivo Contract Research Organization (CRO) Market Regional Analysis/Insights

The in vivo contract research organization (CRO) market is analysed and market size insights and trends are provided by country, product, applications and end-user as referenced above.

The countries covered in the in vivo contract research organization (CRO) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominated other regional markets in terms of revenue share in 2020 with major contribution from the U.S. Furthermore, the region's scientific activities have been strengthened by increased funding. Increasing healthcare spending and the availability of money and grants from government agencies such as the National Institutes of Health (NIH) to support research operations are all contributing to the regional market's revenue growth.

Asia Pacific is the fastest growing market owing to many advanced countries investing in this region and various alterations made by the regulatory market to change the clinical trials assessment standards to match the global platform.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The in vivo contract research organization (CRO) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for in vivo CRO market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the in vivo contract research organization (CRO) market. The data is available for historic period 2010-2020.

Competitive Landscape and In Vivo Contract Research Organization (CRO) Market Share Analysis

생체 내 계약 연구 기관(CRO) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우위가 있습니다. 제공된 위의 데이터 포인트는 생체 내 계약 연구 기관(CRO) 시장과 관련된 회사의 초점에만 관련됩니다.

생체 내 계약 연구 기관(CRO) 시장에서 운영되는 주요 업체는 다음과 같습니다.

• PPD 주식회사(미국)
• 퀸타일스(미국)
• ICON Plc (아일랜드)
• 파렉셀 인터내셔널 코퍼레이션(미국)
• American Preclinical Services, LLC(미국)
• Labcorp 약물 개발(미국)
• 정리 임상 연구(미국)
• WuXi AppTec(중국)
• 시네오스 헬스(미국)
• 에보텍(독일)
• 찰스 리버 연구소(미국)

SKU-68336